Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Allison Whitten Pfizer's LITFULO meets primary endpoints in Phase 3 vitiligo trials Pfizer reported topline results from two Phase 3 trials of LITFULO (ritlecitinib) in nonsegmental vitiligo, with both the 50 and 100 milligram once-daily doses meeting co-primary endpoints for facial and total body repigmentation over placebo at Week 52
The most frequently cited mechanistic findings come from a small group of obese-rodent studies published around the beginning of the 2000s
A supportive approach to your energy and weight goals Natural energy levels Healthy metabolism Focus and clarity Complements GLP-1 programs May regulate appetite Safe, non-stimulant option Fat metabolism Shed journey 3-minute signup, 100% online Receive a personalized plan
Data are unavailable on the toxicity of other preservatives in this age group
Individuals with Digestive Disorders Conditions like Crohns disease, celiac disease, or gastric bypass surgery can impair B12 absorption
US$ 22.17
US$ 29.19
US$ 23.50
US$ 29.22
US$ 20.92
US$ 29.34
US$ 29.16
US$ 21.16
US$ 23.46
